Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
38.92B | 34.85B | 35.85B | 32.81B | 30.18B | Gross Profit |
9.01B | 6.93B | 8.81B | 8.56B | 7.49B | EBIT |
2.67B | 912.00M | 2.75B | 2.66B | 1.76B | EBITDA |
3.91B | 3.12B | 4.03B | 3.85B | 2.88B | Net Income Common Stockholders |
2.30B | 1.36B | 2.06B | 1.92B | 1.56B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
7.46B | 5.08B | 6.26B | 6.53B | 6.43B | Total Assets |
58.40B | 51.30B | 50.32B | 46.04B | 42.94B | Total Debt |
1.22B | 1.15B | 1.24B | 1.34B | 1.44B | Net Debt |
-6.24B | -3.93B | -5.02B | -5.09B | -4.99B | Total Liabilities |
20.44B | 17.40B | 18.27B | 16.66B | 15.86B | Stockholders Equity |
37.88B | 33.82B | 31.95B | 29.23B | 26.93B |
Cash Flow | Free Cash Flow | |||
2.53B | -529.00M | -34.00M | 218.00M | 1.88B | Operating Cash Flow |
4.34B | 1.62B | 1.44B | 2.82B | 3.02B | Investing Cash Flow |
-1.61B | -1.64B | -1.08B | -2.32B | -1.01B | Financing Cash Flow |
-352.00M | -1.17B | -543.00M | -498.00M | -561.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | ¥27.72B | 6.41 | 4.81% | 4.77% | 43.74% | ||
80 Outperform | ¥20.17B | 7.42 | 4.06% | 8.23% | 37.45% | ||
77 Outperform | ¥5.83B | 6.45 | 3.37% | 16.98% | 16.26% | ||
72 Outperform | ¥24.98B | 10.04 | 1.91% | 11.95% | 68.61% | ||
64 Neutral | ¥36.71B | 11.19 | 0.97% | 20.99% | 36.85% | ||
51 Neutral | $2.03B | -1.13 | -21.36% | 3.65% | 2.87% | -30.54% | |
42 Neutral | €13.24B | 7.54 | -1.83% | 0.86% | -23.94% | -110.06% |
Taki Chemical Co., Ltd. has announced the disposal of 7,382 treasury shares as part of a restricted stock compensation plan aimed at incentivizing its Directors and Executive Officers. This move is designed to align the interests of the company’s leadership with those of its shareholders, fostering a long-term commitment to enhancing corporate value. The plan involves a structured allotment of shares with transfer restrictions, ensuring that the shares are retained by the eligible officers during their tenure, thereby strengthening the company’s governance and operational focus.
Taki Chemical Co., Ltd. reported a 6.3% increase in net sales for the first quarter of 2025, with significant growth in operating and ordinary profits. Despite a decrease in comprehensive income, the company forecasts continued growth in net sales and dividends for the fiscal year, indicating a positive outlook for stakeholders.
Taki Chemical Co., Ltd. has completed the payment procedures for the disposal of 7,382 treasury shares as restricted stock compensation, following a resolution from the Board of Directors. This move involves distributing shares to directors and executive officers, potentially impacting the company’s stock management and aligning executive interests with shareholder value.